MRNA, PFE: How Biotech Will Perform In A Post-Covid World

Moderna (MRNA) will lose money in 2023 because they are projecting $6B in R&D and other expenses, says Brad Loncar. He discusses biotech stocks. He notes that companies are focusing on vaccines for other issues like RSV to help make up for lost Covid sales. He then goes over the outlook for vaccine maker, as well as how biotech stocks will perform in a post-Covid world. Tom White then joins to demonstrate example trades using Moderna (MRNA) and Pfizer (PFE). Tune in to find out more about the stock market today.